Sling Therapeutics gets $123M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 16 September, 2026

Real innovation is getting harder to spot. The Endpoints 11 is our read on the private companies clearing a rising bar, revealed at a gala dinner with the founders, investors and editors behind the list. Save on your gala pass with code ELEVEN26.

presented by Pac­ing the Jour­ney: A Frame­work to Com­mer­cial Readi­ness

news Novartis' TREM2 drug fails Phase 2 ALS trial Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial

Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

AI has stopped being a question and started being an answer. Remaking workforces, AI-derived molecules into the clinic, catching record capital against sharpening doubt. What does it mean for biopharma? Find out, join us.

ENDPOINTS PHARMA HHS official Klomp spars with Warren over drug pricing contracts FDA approves first radioligand generic, setting up rivalry with Novartis Centric Compounding recalls three injectables over contamination  FDA leaders say they’ve woven in feedback as expedited trial program goes live

in case you missed it 1. Vera eyes full approval for Trutakna in IgAN following positive readout 2. FDA should require credentials for psychedelic providers, experts say 3. News Briefing Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest deal 4. Axoltis says its Phase 2 study for an experimental ALS drug failed 5. Sionna cuts nearly half of staff as it lines up second attempt at cystic fibrosis 6.